Anthem Biosciences Limited (NSE:ANTHEM)

Market Cap	332.70B
Revenue (ttm)	20.77B +22.3%
Net Income	5.16B +13.6%
EPS	9.21 +14.8%
Shares Out	561.61M
PE Ratio	64.30
Forward PE	52.65
Dividend	n/a
Ex-Dividend Date	n/a

Volume	41,217
Average Volume	189,241
Open	597.10
Previous Close	592.40
Day's Range	590.10 - 601.70
52-Week Range	586.00 - 873.50
Beta	n/a
RSI	34.69
Earnings Date	Feb 5, 2026

About Anthem Biosciences

Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the concept stage; preclinical development; and manufacturing development batches of molecules used for clinical Phase I, II, and III trials up to commercial...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 1,825
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ANTHEM

Financial Performance

In 2024, Anthem Biosciences's revenue was 18.50 billion, an increase of 30.29% compared to the previous year's 14.20 billion. Earnings were 4.51 billion, an increase of 22.86%.